Cardiovascular safety and efficacy of celecoxib: focus on treatment and cardiosomatic rehabilitation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

At present time, due to demographic aging of the population, the number of comorbid diseases significantly increases. The most frequent comorbid age-related diseases is the pathology of the cardiovascular and the locomotor systems. The problem of cardiovascular safety of specific cyclooxygenase-2 inhibitors for cardiosomatic patients is one of the most acute. Previously, the use of non-steroidal anti-inflammatory drugs in patients with coronary artery disease was associated with an increased risk of cardiovascular complications, which limited their use in medical rehabilitation practice in this category of patients. The results of the PRECISION study demonstrate the cardiac safety of selective cyclooxygenase-2 inhibitors, namely celecoxib, which can contribute to the success of treatment of comorbid diseases.

Full Text

Restricted Access

About the authors

N. P Lyamina

FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky" of RMH

Email: lyana_n@mail.ru
MD, Prof., Deputy Director for Science SRI of Cardiology Saratov

E. S Karpova

FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky" of RMH

Saratov

References

  1. Bayliss E.A., Steiner J.F., Fernald D.H., Crane L.A., Main D.S. Description of barriers to self-care by persons with comorbid chronic diseases. Ann. Fam. Med. 2003;1(1): 5-21.
  2. Dickson V.V., Buck Н., Riegel В. A qualitative metaanalysis of heart failure self-care practices among individuals with multiple comorbid conditions. J. Card. Fail. 2011;5(17):413-19.
  3. Fortin M., Bravo G., Hudon C., Vanasse A., Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann. Fam. Med. 2005;3:223-28.
  4. Здравоохранение в России 2015. Государственная служба Росстата www.gks.ru/ free_doc/doc_2015/zdrav15.pdf
  5. Fortin M., Lapointe L., Hudon C., Vanasse A., Ntetu A.L., Maltais D. Multimorbidity and quality of life in primary care: a systematic review. Health Qual. Life Outcomes. 2004;20(2):51.
  6. Аронов Д.М. Успехи и проблемы кардиореабилитации в России. Эффективная фармакотерапия. Кардиология и ангиология. 2011;1:22-7.
  7. Насонов Е.Л. Циклооксигеназа 2 и кардиоваскулярная патология. Сердце. 2004; 4:209-12.
  8. Pramo J., Beloqui O., Orbe J. Cyclooxygenase-2: a new therapeutic target in atherosclerosis? Med. Clin. (Barc) 2006;126(20):782-86.
  9. Sostres C., Gargallo C.J., Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther. 2013;15(Suppl3):S3.
  10. Laine L., White W.B., Rostom A., Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Semin. Arthritis Rheum. 2008;38(3):165-87.
  11. Gislason G.H., Jacobsen S., Rasmussenet J.N., Rasmussen S., Buch P., Friberg J., Schramm T.K., Abildstrom S.Z., Kober L., Madsen M., Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113: 2906-13.
  12. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA. 2006;296:1633-44.
  13. Grosser T., Fries S., Fitz Gerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunities. J. Clin. Invest. 2006; 116(1):4-15.
  14. Каратеев А.Е. Использование целекоксиба в ревматологии, кардиологии, неврологии и онкологии. РМЖ. 2007;22:1660-669.
  15. Harris R. Cyclooxygenase -2 (cox-2) and the inflammogenesis of cancer. Subcell. Biochem. 2007;42:93-126.
  16. Moore R., Derry S., Makinson G., McQuay H. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systemic review and meta-analysis on information from company clinical reports. Arthritis Res. Ther. 2005;7:644-65.
  17. McGettigan P., Henry D. Use of nonsteroidal antiinflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388.
  18. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review ofpopulation-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
  19. Каратеев А.Е. Целекоксиб: оценка эффективности и безопасности во втором десятилетии XXI века. Современная ревматология. 2013; 4:54-61.
  20. drugs.com [интернет] U.S. Pharmaceutical Sales - 2012 [доступ 02.10.2013]. Available from: http://www.drugs.com/stats/top100 /2012/units
  21. Морозова Т.Е., Шмарова Д.Г., Рыкова С.М. Выбор нестероидных противовоспалительных препаратов у больных ревматологического профиля с сопутствующими сердечно-сосудистыми заболеваниями. Лечащий врач. 2016;7:39-46.
  22. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000;343:1520-28.
  23. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б., Кукушкин, М.Л., Дроздов В.Н., Исаков В.А., Насонов Е.Л. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2009.
  24. Zidar N., Odar K., Glavac D., Jerse M., Zupanc T., Stajer D. Cyclooxygenase in normal human tissues -is COX-1 really a constitutive iso form, and COX-2 an inducible isoform?J. Cell. Mol. Med. 2009;13(9 B):3753-63.
  25. Khan K.N., Stanfield K.M., Dannenberg A., Seshan S.V, Baergen R.N., Baron D.A., Soslow R.A. Cyclooxygenase-2 expression in the developing human kidney. Pediatr. Develop. Pathol. 2001;4(5):461-66.
  26. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
  27. Kimmel S.E., Berlin J.A., Reilly M., Jaskowiak J., Kishel L., Chittams J., Strom B.L. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. 2005;142:157-64.
  28. Topol E.J. Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 2004;51:2877-78.
  29. Levesque L.E., Brophy J.M., Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann. Intern. Med. 2005;l42(7):481-89.
  30. Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(11): 1366-72.
  31. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Nørgárd B., Friis S., Sørensen H.T. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. 2005;165: 978-84.
  32. Kingsley G., Smith C., Choy E.H., Scott D.L. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann. Rheum Dis. 2007;66(10):1296-304.
  33. Silverstein F., Faich G., Goldstein J., et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000;84:1247-55.
  34. Singh G., Fort J., Goldstein J., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., Geis G.S. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am. J. Med. 2006;119:255-66.
  35. Nissen S.E., Yeomans N.D., Solomon D.H., Lüscher T.F., Libby P., Husni M.E., Graham D.Y., Borer J.S., Wisniewski L.M., Wolski K.E., Wang Q., Menon V., Ruschitzka F., Gaffney M., Beckerman B., Berger M.F., Bao W., Lincoff A.M.; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N. Engl. J. Med. 2016; 375:2519-29.
  36. Powell K.E., Paluch A.E., Blair S.N. Physical activity for health: What kind? How much? With what intensity? Over what? Ann. Rev. Public Health. 2011;32:349-65.
  37. Кукушкин М.Л. Нейрофизиология боли и обезболивания. Боль. Суставы. Позвоночник. 2011;2:60-5.
  38. Казаков В.Ф., Макарова И.Н., Серяков В.В. и др. Реабилитация при заболеваниях сердечнососудистой системы. М., 2010. 304 с.
  39. Аронов Д.М., Красницкий В.Б., Бубнова М.Г. и др. Влияние физических тренировок на физическую работоспособность, гемодинамику, липиды крови, клиническое течение и прогноз у больных ишемической болезнью сердца после острых коронарных событий при комплексной реабилитации и вторичной профилактике на амбулаторно-поликлиническом этапе (Российское кооперативное исследование). Кардиология. 2009;3(49):49-56.
  40. Национальные рекомендации по остеоартриту. Центры по контролю и профилактике заболеваний и американский фонд по заболеванию артритом, 2010
  41. Луста К.А., Орехов А.Н. Роль провоспалительных и противовоспалительных медиаторов в атерогенезе. Клиническая и экспериментальная морфология. 2014;3:64-74.
  42. Prasad K. C-reactive protein (CRP) - lowering agents. Cardiovasc. Drug Rev. 2006;24(1):33-50.
  43. Chenevard R., Hurlimann D., Bechir M., Enseleit F., Spieker L., Hermann M., Riesen W., Gay S., Gay R.E., Neidhart M., Michel B., Lüscher T.F., Noll G., Ruschitzka F. Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease. Circulation. 2003;107:405-9.
  44. Bogaty P., Brophy J., Noel M., Boyer L., Simard S., Bertrand F., Dagenais G.R. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation. 2004;110 (8):934-39.
  45. Каратеев А.Е. Возможность использования НПВП у больных с ЖКТ- и кардиоваскулярными факторами риска. РМЖ. 2009;7:495.
  46. Chung J.W., Yang H.M., Park K.W., Lee H.Y., Park J.S., Kang H.J., Cho Y.S., Youn T.J., Koo B.K., Chae I.H., Choi D.J., Oh B.H., Park Y.B., Kim H.S. Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: Two-year clinical follow-up of COREA-TAXUS trial. Circ. Cardiovasc. Interv. 2010;3(3):243-48.
  47. Koo B.K., Kim Y.S., Park K.W., Yang H.M., Kwon D.A., Chung J.W., Hahn J.Y., Lee H.Y., Park J.S., Kang H.J., Cho Y.S., Youn T.J., Chung W.Y., Chae I.H., Choi D.J., Oh B.H., Park Y.B., Kim H.S. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007;370(9587):567-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies